Comparison of baseline genomic features detected in BRAF V600 mutant melanoma samples from advanced melanoma patients who differentially responded to BRAF + MEK inhibitor therapy is a promising research approach to better understand tumor response and therapeutic resistance and to optimize treatment selection [13]. This evidence concerns the gene BRAF and neoplasm.